Updates on Use and Monitoring of Direct Thrombin Inhibitors.Clin Lab Med 2026 Jun; 46(2):259-277.CL
Abstract
Direct thrombin inhibitors (DTIs) such as bivalirudin and argatroban have a predictable anticoagulant response, the ability to inhibit thrombin bound to fibrin, and efficacy in thrombotic environments. These properties make them a valuable tool to manage patients at risk of thrombotic events. DTIs require less frequent monitoring and dose adjustments than heparin. Due to poor correlation of activated partial thromboplastin time with DTI concentration, diluted thrombin time is widely used for monitoring bivalirudin anticoagulation. Emerging monitoring methods are promising and reflect the evolution of precision medicine toward more personalized, real-time monitoring techniques that can guide anticoagulation therapy in complex cases.
MeSH
Pub Type(s)
Journal Article
Review
Language
eng
PubMed ID
42140684
Citation
Navaei, Amir, et al. "Updates On Use and Monitoring of Direct Thrombin Inhibitors." Clinics in Laboratory Medicine, vol. 46, no. 2, 2026, pp. 259-277.
Navaei A, Kostousov V, Teruya J. Updates on Use and Monitoring of Direct Thrombin Inhibitors. Clin Lab Med. 2026;46(2):259-277.
Navaei, A., Kostousov, V., & Teruya, J. (2026). Updates on Use and Monitoring of Direct Thrombin Inhibitors. Clinics in Laboratory Medicine, 46(2), 259-277. https://doi.org/10.1016/j.cll.2026.02.011
Navaei A, Kostousov V, Teruya J. Updates On Use and Monitoring of Direct Thrombin Inhibitors. Clin Lab Med. 2026;46(2):259-277. PubMed PMID: 42140684.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Updates on Use and Monitoring of Direct Thrombin Inhibitors.
AU - Navaei,Amir,
AU - Kostousov,Vadim,
AU - Teruya,Jun,
Y1 - 2026/04/01/
PY - 2026/5/16/medline
PY - 2026/5/16/pubmed
PY - 2026/5/15/entrez
KW - Anticoagulants
KW - Argatroban
KW - Bivalirudin
KW - Diluted thrombin time
KW - Direct thrombin inhibitor
KW - Ecarin chromogenic assay
SP - 259
EP - 277
JF - Clinics in laboratory medicine
JO - Clin Lab Med
VL - 46
IS - 2
N2 - Direct thrombin inhibitors (DTIs) such as bivalirudin and argatroban have a predictable anticoagulant response, the ability to inhibit thrombin bound to fibrin, and efficacy in thrombotic environments. These properties make them a valuable tool to manage patients at risk of thrombotic events. DTIs require less frequent monitoring and dose adjustments than heparin. Due to poor correlation of activated partial thromboplastin time with DTI concentration, diluted thrombin time is widely used for monitoring bivalirudin anticoagulation. Emerging monitoring methods are promising and reflect the evolution of precision medicine toward more personalized, real-time monitoring techniques that can guide anticoagulation therapy in complex cases.
SN - 1557-9832
UR - https://www.unboundmedicine.com/prime/citation/42140684/Updates_on_Use_and_Monitoring_of_Direct_Thrombin_Inhibitors.
DB - PRIME
DP - Unbound Medicine
ER -
